×
About 16,283 results

ALLMedicine™ Amyotrophic Lateral Sclerosis Center

Research & Reviews  5,986 results

Short structural variants as informative genetic markers for ALS disease risk and progr...
https://doi.org/10.1186/s12916-021-02206-y 10.3389/fnins.2019.01310 10.1038/s41598-017-10488-7 10.2741/e811 10.1016/j.lfs.2017.12.016 10.1080/21678421.2020.1788092 10.1212/WNL.0000000000004606 10.1002/cpt.288 10.1038/s41467-019-11146-4 10.1186/s13059-019-1707-2 10.1038/ng2042 10.1186/s13059-019-1828-7 10.1038/nrg2554 10.1038/nature15393 10.3389/fnins.2020.00047 10.1038/ng.3834 10.1016/j.ajhg.2013.01.011 10.1038/s41598-021-85510-0 10.1038/s41531-021-00200-y 10.1038/tpj.2009.69 10.1016/j.nbd.2020.105156 10.1002/humu.23023 10.1038/ng.3622 10.1038/s41467-017-00471-1 10.1016/j.neuron.2018.02.027 10.1517/17425255.2016.1133586 10.1126/science.8346443 10.3390/brainsci11030332 10.1038/clpt.2012.222 10.1016/j.trci.2019.09.010 10.1016/S1474-4422(14)70219-4 10.1038/s41588-019-0521-9 10.1016/j.yexcr.2014.01.020 10.1093/hmg/7.13.2045 10.1212/01.wnl.0000343509.76828.2a 10.1016/j.cell.2019.04.038 10.1016/j.ajhg.2020.06.019 10.1056/NEJMoa2003715 10.1038/s41593-018-0293-z 10.1172/JCI139741 10.1038/s41467-019-13144-y 10.1038/ng.3314 10.3389/fncel.2013.00253 10.1016/j.jbior.2015.10.006 10.1002/med.21661 10.1038/s41582-018-0058-z 10.1186/s13643-018-0913-4 10.5692/clinicalneurol.cn-001220
BMC Medicine; Theunissen F, Flynn LL et. al.

Jan 18th, 2022 - There is considerable variability in disease progression for patients with amyotrophic lateral sclerosis (ALS) including the age of disease onset, site of disease onset, and survival time. There is growing evidence that short structural variations...

Lysosomal dysfunction in neurodegeneration: emerging concepts and methods.
https://doi.org/10.1016/j.tins.2021.12.004
Trends in Neurosciences; Udayar V, Chen Y et. al.

Jan 18th, 2022 - The understanding of lysosomes has come a long way since the initial discovery of their role in degrading cellular waste. The lysosome is now recognized as a highly dynamic organelle positioned at the crossroads of cell signaling, transcription, a...

A multidimensional facial surface EMG analysis for objective assessment of bulbar invol...
https://doi.org/10.1016/j.clinph.2021.11.074
Clinical Neurophysiology : Official Journal of the Intern... Rong P, Pattee GL

Jan 17th, 2022 - To develop a multidimensional facial surface electromyographic (EMG) analysis for assessing bulbar involvement in amyotrophic lateral sclerosis (ALS). Fifty-four linear and nonlinear features were extracted from the surface EMG recordings for mass...

The Cyanotoxin 2,4-DAB Reduces Viability and Causes Behavioral and Molecular Dysfunctio...
https://doi.org/10.1007/s12640-021-00465-4
Neurotoxicity Research; Martin RM, Bereman MS et. al.

Jan 15th, 2022 - Exposure to cyanotoxins has been linked to neurodegenerative diseases, including amyotrophic lateral sclerosis, Alzheimer's, and Parkinson's disease. While the cyanotoxin β-methylamino-L-alanine (BMAA) has received much attention, cyanobacteria pr...

Genetic testing in motor neurone disease.
https://doi.org/10.1136/practneurol-2021-002989
Practical Neurology; Dharmadasa T, Scaber J et. al.

Jan 15th, 2022 - A minority (10%-15%) of cases of amyotrophic lateral sclerosis (ALS), the most common form of motor neurone disease (MND), are currently attributable to pathological variants in a single identifiable gene. With the emergence of new therapies targe...

see more →

Guidelines  3 results

Provisional best practices guidelines for the evaluation of bulbar dysfunction in amyot...
https://doi.org/10.1002/mus.26408
Muscle & Nerve; Pattee GL, Plowman EK et. al.

Jan 9th, 2019 - Universally established comprehensive clinical bulbar scales objectively assessing disease progression in amyotrophic lateral sclerosis (ALS) are currently lacking. The goal of this working group project is to design a best practice set of provisi...

ESPEN guideline clinical nutrition in neurology.
https://doi.org/10.1016/j.clnu.2017.09.003
Clinical Nutrition (Edinburgh, Scotland); Burgos R, Bretón I et. al.

Dec 25th, 2017 - Neurological diseases are frequently associated with swallowing disorders and malnutrition. Moreover, patients with neurological diseases are at increased risk of micronutrient deficiency and dehydration. On the other hand, nutritional factors may...

Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764728
Neurology Miller RG, Jackson CE et. al.

Oct 14th, 2009 - To systematically review evidence bearing on the management of patients with amyotrophic lateral sclerosis (ALS). The authors analyzed studies from 1998 to 2007 to update the 1999 practice parameter. Topics covered in this section include breaking...

see more →

Drugs  17 results see all →

Clinicaltrials.gov  184 results

A Study of BIIB067 When Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation
https://clinicaltrials.gov/ct2/show/NCT04856982

Jan 14th, 2022 - The primary objective of this study is to evaluate the efficacy of BIIB067 when initiated in presymptomatic adult carriers of a superoxide dismutase 1 (SOD1) mutation with elevated neurofilament (NF). The secondary objectives of this study are to ...

HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS)
https://clinicaltrials.gov/ct2/show/NCT02437110

Jan 13th, 2022 - Objective: In this Phase I, proof-of-concept study, we aim to determine whether an antiretroviral regimen approved to treat human immunodeficiency virus (HIV) infection would also suppress levels of Human Endogenous Retrovirus-K (HERV-K) found to ...

Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS
https://clinicaltrials.gov/ct2/show/NCT04569084

Jan 12th, 2022 - To evaluate and compare the efficacy of two dosing regimens of oral edaravone in subjects with amyotrophic lateral sclerosis (ALS) based on the change in ALS Functional Rating Scale- Revised (ALSFRS-R) score from baseline up to Week 48:

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of FAB122 in Patients With Amyotrophic Lateral Sclerosis
https://clinicaltrials.gov/ct2/show/NCT05178810

Jan 5th, 2022 - Multicenter, multinational, double-blind, randomized (2:1), placebo-controlled Phase III study to investigate the efficacy and safety of 100 mg FAB122 once daily as oral formulation in ALS patients.

Clinical Manifestations and Biomarkers in Amyotrophic Lateral Sclerosis Type 4 and Other Inherited Neurological Disorders of RNA Processing
https://clinicaltrials.gov/ct2/show/NCT04394871

Dec 16th, 2021 - Objective: Amyotrophic lateral sclerosis type 4 (ALS4) is an inherited form of motor neuron disease caused by mutation in the senataxin (SETX) gene. The main goal of this study will be to collect clinical and molecular biomarkers from patients wit...

see more →

News  314 results

Long-Term Adjunctive Edaravone for ALS: Latest Findings
https://www.medscape.com/viewarticle/966717

Jan 17th, 2022 - Long-term add-on treatment with intravenous (IV) edaravone is not associated with any change in the progression of amyotrophic lateral sclerosis (ALS), new research shows. These findings contradict those from the drug trial the US Food and Drug Ad...

Long NFL Careers Significantly Boost ALS Risk, but What's at Play?
https://www.medscape.com/viewarticle/964853

Dec 15th, 2021 - National Football League players are nearly four times more likely to develop amyotrophic lateral sclerosis (ALS) than men in the general population, with long-term players at greatest risk, a new study shows. The findings are the latest to show i...

ALS-Lipids Link, Eye Disease and Heightened Dementia Risk; Parkinson's and NSAIDs
https://www.medpagetoday.com/neurology/generalneurology/94613

Sep 21st, 2021 - Elevated levels of HDL and apolipoprotein A1 were linked to a lower risk of amyotrophic lateral sclerosis (ALS), U.K. Biobank data showed. (Journal of Neurology, Neurosurgery, & Psychiatry) Also from the U.K. Biobank cohort: age-related macular de...

Lipid Levels Tied to ALS Risk
https://www.medscape.com/viewarticle/958730

Sep 14th, 2021 - Elevated levels of high-density lipoprotein (HDL) and apolipoprotein A1 (apoA1) are associated with a reduced risk for amyotrophic lateral sclerosis (ALS), new research shows. The study also linked a higher ratio of total cholesterol to HDL with a...

AstraZeneca's Antibody Therapy Prevents COVID-19, Study Shows
https://www.medscape.com/viewarticle/956953

Aug 23rd, 2021 - (Reuters) - AstraZeneca's new antibody therapy reduced the risk of people developing COVID-19 symptoms by 77% in a late-stage trial, putting the drugmaker on track to offer protection to those who respond poorly to vaccines. The company said on Fr...

see more →

Patient Education  9 results see all →